Metastatic-Breast-Cancer

Conference Coverage

Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib

12/07/2021

Janelle Bradley

Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.

Study findings show patients...

12/07/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer

12/07/2021

Janelle Bradley

Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...

Use of a blood-based biomarker...

12/07/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting

12/07/2021

Janelle Bradley

A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.

A study presented at the 2021...

12/07/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer

12/06/2021

Janelle Bradley

Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.

Medical oncologists reported...

12/06/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer

12/06/2021

Janelle Bradley

The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.

The inclusion of...

12/06/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases

12/06/2021

Janelle Bradley

Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.

Palbociclib plus letrozole is...

12/06/2021

Journal of Clinical Pathways

Metastatic Breast Cancer

Tracks

Specialties

Events

Year Round Education

HMP Global Products